Will FDA quickly review a Lilly drug to alleviate cost concerns for Alzheimer’s treatments?

In an unexpected move, U.S regulators granted Eli Lilly (LLY) a breakthrough designation for its experimental Alzheimer’s drug, raising intriguing questions about competition and pricing in a quickly evolving marketplace already filled with controversy.

This was the second time this week, in fact, that the Food and Drug Administration granted this type of designation to an Alzheimer’s drug being developed, the other bestowed on Biogen (BIIB) and Eisai (ESALY). The companies earlier this month won approval for their Aduhelm medication despite furious debate over clinical data, regulatory standards, and the ensuing cost to the U.S. health care system.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Source link


The leading source for trustworthy and timely health and medical news and information. Providing credible health information, supportive community, and educational services by blending award-winning expertise in content, community services, expert commentary, and medical review. Everything about health is here with the difference of Dr.About

Related Articles

Leave a Reply

Back to top button